Roche ( RHHBF) ( RHHBY) shares fell after the Swiss drugmaker’s investigational breast cancer pill failed to meet the primary goal of a late-stage breast cancer trial.
The firm also said this week that it plans to submit data to the FDA from an adjuvant trial of giredestrant in ER-positive, HER2-negative breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results